Unlock instant, AI-driven research and patent intelligence for your innovation.

Diol group/triol group rare ginsenoside composition with antitumor activity

A technology of antitumor activity and ginsenoside, applied in the field of biomedicine

Active Publication Date: 2020-02-07
SHAANXI GIANT BIOTECHNOLOGY CO LTD
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] It has been reported in domestic literature that some ginsenosides alone have anti-tumor effects, but there are few reports on how to combine specific types of ginsenoside monomers to obtain better anti-tumor effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diol group/triol group rare ginsenoside composition with antitumor activity
  • Diol group/triol group rare ginsenoside composition with antitumor activity
  • Diol group/triol group rare ginsenoside composition with antitumor activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] Aqueous solutions of Rk1, Rg5, Rk3 and Rh4 with a concentration of 500 ug / ml were prepared respectively, which were called Rk1-1, Rg5-1, Rk3-1 and Rh4-1 respectively.

[0059] According to Rk1:Rg5:Rk3:Rh4=15:50:10:25 (weight ratio), an aqueous solution containing Rk1, Rg5, Rk3 and Rh4 with a total concentration of 500ug / ml was prepared, which was called Composition 1.

[0060] Using the above-mentioned Rk1-1, Rg5-1, Rk3-1, Rh4-1 and composition 1, as well as lung cancer cell Nci-H460, colon cancer cell Caco-2, gastric cancer cell SGC-7901, and breast cancer cell MCF-7 Cancer cells were subjected to cancer cell inhibition experiments. Specific steps are as follows:

[0061] (1) Human estrogen receptor-positive breast cancer cell line MCF-7, human lung cancer cell line NCI-H460, human gastric cancer cell line SGC-7901, human colon cancer cell line Caco-2, use RPMI 1640 cell culture medium, this All four cells are adherent cells. Centrifuge the frozen cell solution at 1...

Embodiment 2

[0070] Aqueous solutions of Rk1, Rg5, Rk3 and Rh4 with a concentration of 250 ug / ml were prepared respectively, which were called Rk1-2, Rg5-2, Rk3-2 and Rh4-2 respectively.

[0071] According to Rk1:Rg5:Rk3:Rh4=10:20:60:10 (weight ratio), an aqueous solution containing Rk1, Rg5, Rk3 and Rh4 with a total concentration of 250ug / ml was prepared, which is called composition 2.

[0072] The cancer cell inhibition experiment was carried out as in Example 1 using the above Rk1-2, Rg5-2, Rk3-2, Rh4-2 and Composition 2.

[0073] Table 2 shows the inhibition rates of the above-mentioned Rk1-2, Rg5-2, Rk3-2, Rh4-2 and Composition 2 on various cancer cells.

[0074] Table 2

[0075]

[0076] The values ​​in the table are inhibition rate, unit %

Embodiment 3

[0078] Aqueous solutions of Rk1, Rg5, Rk3 and Rh4 with a concentration of 125ug / ml were prepared respectively, which were called Rk1-3, Rg5-3, Rk3-3 and Rh4-3 respectively.

[0079] An aqueous solution containing Rk1, Rg5, Rk3 and Rh4 with a total concentration of 125ug / ml was prepared according to Rk1:Rg5:Rk3:Rh4=25:25:25:25 (weight ratio), which is called composition 3.

[0080] Cancer cell inhibition experiments were carried out as in Example 1 using the above Rk1-3, Rg5-3, Rk3-3, Rh4-3 and Composition 3.

[0081] Table 3 shows the inhibition rates of the above-mentioned Rk1-3, Rg5-3, Rk3-3, Rh4-3 and Composition 3 on various cancer cells.

[0082] table 3

[0083]

[0084] The values ​​in the table are inhibition rate, unit %

[0085] From the results of Examples 1 to 3 above, it can be seen that compared with Rk1-3, Rg5-3, Rk3-3, and Rh4-3 monomers, the composition of the present invention can significantly improve the cancer cell inhibition rate, and by adjusting th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a diol / triol rare ginsenoside composition with anti-tumor activity. The rare ginsenoside composition is prepared from the following components, calculated according to 100 parts by weight of total ginsenoside in the rare ginsenoside composition, in parts by weight: 5-85 parts of ginsenoside Rk1, 5 to 85 parts of ginsenoside Rg5, 5 to 85 parts of ginsenoside Rk3 and 5 to 85 parts of ginsenoside Rh4.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a rare ginsenoside composition with antitumor activity comprising ginsenosides Rk1, Rg5, Rk3 and Rh4. Background technique [0002] Cancer is the second most threatening human disease after cerebrovascular disease. The incidence of cancer in my country exceeds 3 million people every year, and the incidence of lung cancer, breast cancer, and esophageal cancer increases year by year, among which the annual growth rate of lung cancer incidence is 26.8%, and the annual growth rate of breast cancer incidence is 6.8%. Over the past 30 years, the mortality rate of breast cancer has increased by 96%, and the mortality rate of lung cancer has soared by 465%. my country's cancer prevention and control work is urgent and the situation is grim. [0003] At present, the commonly used clinical cancer treatment methods include surgical resection, radiotherapy, chemotherapy, etc., and these methods h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P35/00
CPCA61K31/704A61K2300/00
Inventor 段志广范代娣马晓轩刘彦楠李伟娜张婧婧严建亚
Owner SHAANXI GIANT BIOTECHNOLOGY CO LTD